Outcomes for patients with IDH-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: Post-transplant outcomes of IDH-mutated acute myeloid leukemia

Acute myeloid leukemia (AML) is a lethal hematologic disease characterized by the clonal expansion of malignant myeloid progenitor cells. For many patients, particularly those with poor-risk disease, allogeneic hematopoietic cell transplant (HCT) is a potentially curative post-remission treatment modality1. However, relapse of AML remains the major cause of treatment failure following allogeneic HCT2, 3. For all adult AML patients receiving an allogeneic HCT in the last decade, the 3-year overall-survival is 49% ± 1% according to the Center for International Blood and Marrow Transplant Research (CIBMTR)3.

Source: Biology of Blood and Marrow Transplantation - February 25, 2021 Category: Hematology Authors: Evan C. Chen, Shuli Li, Ann-Kathrin Eisfeld, Marlise R. Luskin, Alice Mims, Daniel Jones, Joseph H. Antin, Corey S. Cutler, John Koreth, Vincent T. Ho, Mahasweta Gooptu, Rizwan Romee, Areej El-Jawahri, Steven L. McAfee, Zachariah DeFilipp, Robert J. Soiff Source Type: research